10-Q · August 3, 2026
CRISPR Therapeutics posted substantially improved Q2 results: revenue increased to $10.181 million, net loss narrowed to $91.154 million, and diluted EPS improved to negative $0.94 from negative $2.40 a year earlier.…
Earnings analysis · 10-Q
CRSP earnings analysis
Filed November 2, 2026 · Our reading of the company's report
The latest report
CRISPR Therapeutics delivered $12.669 million of third-quarter revenue, up from $10 million in the prior quarter, with CASGEVY revenue reaching $99 million and rising 30% sequentially. However, diluted EPS worsened to…
Read full summary
CRISPR Therapeutics delivered $12.669 million of third-quarter revenue, up from $10 million in the prior quarter, with CASGEVY revenue reaching $99 million and rising 30% sequentially. However, diluted EPS worsened to negative $1.15 from negative $0.94 and net loss widened to $111.437 million from $106.441 million. Liquidity remained strong at $2,276.6 million, but the filing provided no quantitative forward guidance; management also reported no material changes to previously disclosed risk factors.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.15
- Gross margin
- 100.0%
- Segment
- CASGEVY: $99 million of revenue, up 30% quarter-over-quarter
What stood out
-
Revenue accelerated sequentially
Third-quarter revenue was $12.669 million, up from $10 million in the prior quarter and approximately $0.889 million in the prior-year quarter.
-
CASGEVY growth remained strong
CASGEVY revenue reached $99 million, increasing 30% quarter-over-quarter, indicating continued commercial momentum for the partnered product.
-
Liquidity remained substantial
Cash, cash equivalents and marketable securities totaled $2,276.6 million as of September 30, 2026, providing substantial liquidity.
-
Losses widened sequentially
The company reported diluted EPS of negative $1.15 versus negative $0.94 in the prior quarter, while net loss increased to $111.437 million from $106.441 million.
-
No material inflation impact
Management stated that inflation did not have a material effect during the three and nine months ended September 30, 2026 and 2025.
-
No control deficiencies reported
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2026, with no material changes in internal control during the quarter.
What to watch
-
Operating losses remain substantial
Net loss increased to $111.437 million from $106.441 million in the prior quarter, and diluted EPS declined to negative $1.15 from negative $0.94, highlighting continuing cash-burn and execution risk.
-
Investment portfolio rate exposure
The company holds $2,276.6 million in cash, cash equivalents and marketable securities, primarily in fixed-income instruments; although management views interest-rate exposure as immaterial, a 1% rate movement would affect portfolio fair value.
-
Ongoing intellectual-property litigation risk
ToolGen initiated patent litigation in the fourth quarter of 2025 alleging CASGEVY infringement, although CRISPR Therapeutics was dismissed without prejudice in April 2026; management stated there were no claims or actions likely to have a material adverse effect.
Management's outlook
The 10-Q does not provide quantitative revenue or EPS guidance. No forward revenue or EPS outlook was disclosed.
Earlier filings 4
10-Q · May 4, 2026
CRISPR Therapeutics reported Q1 2026 results showing total revenue of $1.458 million, a decline from $1 million year-over-year, while net loss improved to $122.9 million from $136 million last year. R&D and G&A expenses…
10-K · February 12, 2026
CRISPR Therapeutics positions itself as a leader in CRISPR/Cas9-based therapeutics with an approved product (CASGEVY) and a diversified pipeline across hemoglobinopathies, in vivo LNP editing, CAR T and regenerative…
10-Q · May 6, 2025
CRISPR Therapeutics reported Q1 2025 revenue of $865,000 and a GAAP net loss of $135.996 million (EPS -$1.58). Revenue rose year-over-year but the company recorded wider operating and net losses, negative operating cash…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.